OnCore Biopharma, Tekmira deal

OnCore will merge with a wholly owned subsidiary of Tekmira in a deal that the companies say value the the combined companies at about $750 million, based on Tekmira’s close of $15.70 on Jan. 9, before the deal was announced. Former OnCore shareholders would hold about 50% of Tekmira’s outstanding shares. ...